firstwordpharma.com
After recent Crohn's nod, J&J builds out case for fully subQ Tremfya in UC
Cure8 flagged this item because the article title and available source metadata connect it to Ulcerative colitis, Crohn's disease, Guselkumab, and IL-23 inhibitor. We do not yet have enough reliable article text to summarize the details.
This may be most useful for Clinicians and Patients On Biologics following Ulcerative colitis, Crohn's disease, Guselkumab, IL-23 inhibitor, and Medications.
What To Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a market or business news related to Ulcerative colitis, Crohn's disease, Guselkumab, and IL-23 inhibitor. Use the original source link for the full details.
Because the source may be tied to a company, announcement, or business update, it is worth reading the original article for context and limitations.
